Current Problems in Surgery
Volume 44, Issue 10 , Pages 635-675 , October 2007

The Appropriate Use of Antibiotics in Surgery: A Review of Surgical Infections

  • Traci L. Hedrick, MD

      Affiliations

    • Resident in Surgery, University of Virginia School of Medicine, Charlottesville, Virginia
    • ,
  • Philip W. Smith, MD

      Affiliations

    • Resident in Surgery, University of Virginia School of Medicine, Charlottesville, Virginia
    • ,
  • Leo M. Gazoni, MD

      Affiliations

    • Resident in Surgery, University of Virginia School of Medicine, Charlottesville, Virginia
    • ,
  • Robert G. Sawyer, MD

      Affiliations

    • Professor of Surgery, Medical Co-Director, Surgical Trauma ICU, University of Virginia School of Medicine, Charlottesville, Virginia

References 

  1. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee (Guideline for Prevention of Surgical Site Infection, 1999). Am J Infect Control. 1999;27(2):97–132quiz 3-4; discussion 96.
  2. Guidelines for preventing health-care-associated pneumonia, 2003 recommendations of the CDC and the Healthcare Infection Control Practices Advisory Committee. Respir Care. 2004;49:926–939
  3. Bailly P, Lallemand S, Thouverez M, Talon D. Multicentre study on the appropriateness of surgical antibiotic prophylaxis. J Hosp Infect. 2001;49:135–138
  4. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 2004;38:1706–1715
  5. Barie PS, Eachempati SR. Surgical site infections. Surg Clin North Am. 2005;85:1115–1135
  6. Stone HH, Hooper CA, Kolb LD, Geheber CE, Dawkins EJ. Antibiotic prophylaxis in gastric, biliary and colonic surgery. Ann Surg. 1976;184:443–452
  7. Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med. 1992;326:281–286
  8. Heineck I, Ferreira MBC, Schenkel EP. Prescribing practice for antibiotic prophylaxis for 3 commonly performed surgeries in a teaching hospital in Brazil. Am J Infect Control. 1999;27:296–300
  9. Vaisbrud V, Raveh D, Schlesinger Y, Yinnon AM. Surveillance of Antimicrobial Prophylaxis for Surgical Procedures. Infect Control Hosp Epidemiol. 1999;20:610–613
  10. Hosoglu S, Sunbul M, Erol S, et al. A National Survey of Surgical Antibiotic Prophylaxis in Turkey. Infect Control Hosp Epidemiol. 2003;24:758–761
  11. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg. 2005;189:395–404
  12. Platt R, Zaleznik DF, Hopkins CC, et al. Perioperative antibiotic prophylaxis for herniorrhaphy and breast surgery. N Engl J Med. 1990;322:153–160
  13. Platt R, Zucker JR, Zaleznik DF, et al. Prophylaxis against wound infection following herniorrhaphy or breast surgery. J Infect Dis. 1992;166:556–560
  14. Platt R, Zucker JR, Zaleznik DF, et al. Perioperative antibiotic prophylaxis and wound infection following breast surgery. J Antimicrob Chemother. 1993;31(suppl B):43–48
  15. Cunningham M, Bunn F, Handscomb K. Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. Cochrane Database Syst Rev. 2006;2:CD005360
  16. Lazorthes F, Chiotasso P, Massip P, Materre JP, Sarkissian M. Local antibiotic prophylaxis in inguinal hernia repair. Surg Gynecol Obstet. 1992;175:569–570
  17. Celdran A, Frieyro O, de la Pinta JC, et al. The role of antibiotic prophylaxis on wound infection after mesh hernia repair under local anesthesia on an ambulatory basis. Hernia. 2004;8:20–22
  18. Yerdel MA, Akin EB, Dolalan S, et al. Effect of single-dose prophylactic ampicillin and sulbactam on wound infection after tension-free inguinal hernia repair with polypropylene mesh: the randomized, double-blind, prospective trial. Ann Surg. 2001;233:26–33
  19. Taylor EW, Byrne DJ, Leaper DJ, Karran SJ, Browne MK, Mitchell KJ. Antibiotic prophylaxis and open groin hernia repair. World J Surg. 1997;21:811–814discussion 4-5.
  20. Perez AR, Roxas MF, Hilvano SS. A randomized, double-blind, placebo-controlled trial to determine effectiveness of antibiotic prophylaxis for tension-free mesh herniorrhaphy. J Am Coll Surg. 2005;200:393–397discussion 7-8.
  21. Aufenacker TJ, van Geldere D, van Mesdag T, et al. The role of antibiotic prophylaxis in prevention of wound infection after Lichtenstein open mesh repair of primary inguinal hernia: a multicenter double-blind randomized controlled trial. Ann Surg. 2004;240:955–960discussion 60-1.
  22. Aufenacker TJ, Koelemay MJ, Gouma DJ, Simons MP. Systematic review and meta-analysis of the effectiveness of antibiotic prophylaxis in prevention of wound infection after mesh repair of abdominal wall hernia. Br J Surg. 2005;93:5–10
  23. Nichols RL. Preventing surgical site infections: a surgeon’s perspective. Emerg Infect Dis. 2001;7:220–224
  24. Milano CA, Kesler K, Archibald N, Sexton DJ, Jones RH. Mediastinitis after coronary artery bypass graft surgery (Risk factors and long-term survival). Circulation. 1995;92:2245–2251
  25. Stamm AM, Long MN, Belcher B. Higher overall nosocomial infection rate because of increased attack rate of methicillin-resistant Staphylococcus aureus. Am J Infect Control. 1993;21:70–74
  26. Edwards FH, Engelman RM, Houck P, Shahian DM, Bridges CR. The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic prophylaxis in cardiac surgery, part I: duration. Ann Thorac Surg. 2006;81:397–404
  27. Harbarth S, Samore MH, Lichtenberg D, Carmeli Y. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. Circulation. 2000;101:2916–2921
  28. Manian FA, Meyer PL, Setzer J, Senkel D. Surgical site infections associated with methicillin-resistant Staphylococcus aureus: do postoperative factors play a role?. Clin Infect Dis. 2003;36:863–868
  29. Caffarelli AD, Holden JP, Baron EJ, et al. Plasma cefazolin levels during cardiovascular surgery: effects of cardiopulmonary bypass and profound hypothermic circulatory arrest. J Thorac Cardiovasc Surg. 2006;131:1338–1343
  30. Zanetti G, Platt R. Antibiotic prophylaxis for cardiac surgery: does the past predict the future?. Clin Infect Dis. 2004;38:1364–1366
  31. L’Ecuyer PB, Murphy D, Little JR, Fraser VJ. The epidemiology of chest and leg wound infections following cardiothoracic surgery. Clin Infect Dis. 1996;22:424–429
  32. Finkelstein R, Rabino G, Mashiah T, et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg. 2002;123:326–332
  33. Smith TL, Pearson ML, Wilcox KR, et al. Glycopeptide-Intermediate Staphylococcus aureus Working Group Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med. 1999;340:493–501
  34. Nosocomial enterococci resistant to vancomycin—United States, 1989-1993. MMWR Morb Mortal Wkly Rep. 1993;42(30):597–599
  35. Bolon MK, Morlote M, Weber SG, Koplan B, Carmeli Y, Wright SB. Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. Clin Infect Dis. 2004;38:1357–1363
  36. Washington JA, Dearing WH, Judd ES, Elveback LR. Effect of preoperative antibiotic regimen on development of infection after intestinal surgery: prospective, randomized, double-blind study. Ann Surg. 1974;180:567–572
  37. Baum ML, Anish DS, Chalmers TC, Sacks HS, Smith H, Fagerstrom RM. A survey of clinical trials of antibiotic prophylaxis in colon surgery: evidence against further use of no-treatment controls. N Engl J Med. 1981;305:795–799
  38. Malangoni MA, Song J, Herrington J, Choudhri S, Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg. 2006;244:204–211
  39. Lewis RT. Oral versus systemic antibiotic prophylaxis in elective colon surgery: a randomized study and meta-analysis send a message from the 1990s. Can J Surg. 2002;45:173–180
  40. Espin-Basany E, Sanchez-Garcia JL, Lopez-Cano M, et al. Prospective, randomised study on antibiotic prophylaxis in colorectal surgery (Is it really necessary to use oral antibiotics?). Int J Colorectal Dis. 2005;20:542–546
  41. Itani KM, Wilson SE, Awad SS, Jensen EH, Finn TS, Abramson MA. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med. 2006;355:2640–2651
  42. Smith RL, Bohl JK, McElearney ST, et al. Wound infection after elective colorectal resection. Ann Surg. 2004;239:599–605discussion 607.
  43. Fullen WD, Hunt J, Altemeier WA. Prophylactic antibiotics in penetrating wounds of the abdomen. J Trauma. 1972;12:282–289
  44. Thadepalli H, Gorbach SL, Broido PW, Norsen J, Nyhus L. Abdominal trauma, anaerobes, and antibiotics. Surg Gynecol Obstet. 1973;137:270–276
  45. Luchette FA, Borzotta AP, Croce MA, et al. Practice management guidelines for prophylactic antibiotic use in penetrating abdominal trauma: the EAST Practice Management Guidelines Work Group. J Trauma. 2000;48:508–518
  46. Bozorgzadeh A, Pizzi WF, Barie PS, et al. The duration of antibiotic administration in penetrating abdominal trauma. Am J Surg. 1999;177:125–131
  47. Fabian TC, Croce MA, Payne LW, Minard G, Pritchard FE, Kudsk KA. Duration of antibiotic therapy for penetrating abdominal trauma: a prospective trial. Surgery. 1992;112:788–794discussion 94-5.
  48. Cornwell EE, Dougherty WR, Berne TV, et al. Duration of antibiotic prophylaxis in high-risk patients with penetrating abdominal trauma: a prospective randomized trial. J Gastrointest Surg. 1999;3:648–653
  49. Kirton OC, O’Neill PA, Kestner M, Tortella BJ. Perioperative antibiotic use in high-risk penetrating hollow viscus injury: a prospective randomized, double-blind, placebo-control trial of 24 hours versus 5 days. J Trauma. 2000;49:822–832
  50. Hoth JJ, Franklin GA, Stassen NA, Girard SM, Rodriguez RJ, Rodriguez JL. Prophylactic antibiotics adversely affect nosocomial pneumonia in trauma patients. J Trauma. 2003;55:249–254
  51. Hadjiminas D, Cheadle WG, Spain DA, et al. Antibiotic overkill of trauma victims?. Am J Surg. 1994;168:288–290
  52. Delgado G, Barletta JF, Kanji S, Tyburski JG, Wilson RF, Devlin JW. Characteristics of prophylactic antibiotic strategies after penetrating abdominal trauma at a level I urban trauma center: a comparison with the East guidelines. J Trauma. 2002;53:673–678
  53. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect (Larchmt). 2002;3:175–233
  54. Bohnen JM, Solomkin JS, Dellinger EP, Bjornson HS, Page CP. Guidelines for clinical care: anti-infective agents for intra-abdominal infection (A Surgical Infection Society policy statement). Arch Surg. 1992;127:83–89discussion 89.
  55. Wong PF, Gilliam AD, Kumar S, Shenfine J, O’Dair GN, Leaper DJ. Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. Cochrane Database Syst Rev. 2005;2:CD004539
  56. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis. 2003;37:997–1005
  57. Krobot K, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis. 2004;23:682–687
  58. Cattan P, Yin DD, Sarfati E, Lyu R, De Zelicourt M, Fagnani F. Cost of care for inpatients with community-acquired intra-abdominal infections. Eur J Clin Microbiol Infect Dis. 2002;21:787–793
  59. Hopkins JA, Lee JC, Wilson SE. Susceptibility of intra-abdominal isolates at operation: a predictor of postoperative infection. Am Surg. 1993;59:791–796
  60. Dougherty SH. Antimicrobial culture and susceptibility testing has little value for routine management of secondary bacterial peritonitis. Clin Infect Dis. 1997;25(suppl 2):S258–S261
  61. Falagas ME, Barefoot L, Griffith J, Ruthazar R, Snydman DR. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis. 1996;15:913–921
  62. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg. 1991;214:543–549
  63. Gorecki P, Schein M, Rucinski JC, Wise L. Antibiotic administration in patients undergoing common surgical procedures in a community teaching hospital: the chaos continues. World J Surg. 1999;23:429–432discussion 33.
  64. Wasey N, Baughan J, de Gara CJ. Prophylaxis in elective colorectal surgery: the cost of ignoring the evidence. Can J Surg. 2003;46:279–284
  65. Hedrick TL, Sawyer RG. Duration of antimicrobial therapy in intra-abdominal infections. Infect Med. 2004;21:506–510
  66. Smith JA, Bell GA, Murphy J, Forward AD, Forget JP. Evaluation of the use of a protocol in the antimicrobial treatment of intra-abdominal sepsis. J Hosp Infect. 1985;6:60–64
  67. Andaker L, Hojer H, Kihlstrom E, Lindhagen J. Stratified duration of prophylactic antimicrobial treatment in emergency abdominal surgery (Metronidazole-fosfomycin vs. metronidazole-gentamicin in 381 patients). Acta Chir Scand. 1987;153:185–192
  68. Schein M, Assalia A, Bachus H. Minimal antibiotic therapy after emergency abdominal surgery: a prospective study. Br J Surg. 1994;81:989–991
  69. Taylor E, Dev V, Shah D, Festekjian J, Gaw F. Complicated appendicitis: is there a minimum intravenous antibiotic requirement? (A prospective randomized trial). Am Surg. 2000;66:887–890
  70. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infect (Larchmt). 2002;3:161–173
  71. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666–674
  72. DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother. 2004;53(2):ii37–ii50
  73. Sachs MK. The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med. 1990;150:1907–1912
  74. Sigurdsson AF, Gudmundsson S. The etiology of bacterial cellulitis as determined by fine-needle aspiration. Scand J Infect Dis. 1989;21:537–542
  75. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004;164:1669–1674
  76. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373–1406
  77. Paydar KZ, Hansen SL, Charlebois ED, Harris HW, Young DM. Inappropriate antibiotic use in soft tissue infections. Arch Surg. 2006;141(9):850–854discussion 5-6.
  78. Fung HB, Chang JY, Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs. 2003;63:1459–1480
  79. Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents. 2005;26:357–365
  80. Fabian TC, File TM, Embil JM, et al. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Surg Infect (Larchmt). 2005;6:269–282
  81. Gesser RM, McCarroll KA, Woods GL. Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections. J Infect. 2004;48:32–38
  82. Solomkin J, Teppler H, Graham DR, et al. Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam. J Antimicrob Chemother. 2004;53(2):ii51–ii57
  83. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2000;44:3408–3413
  84. Jones ME, Visser MR, Klootwijk M, Heisig P, Verhoef J, Schmitz FJ. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother. 1999;43:421–423
  85. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49:2260–2266
  86. McKinnon PS, Sorensen SV, Liu LZ, Itani KM. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother. 2006;40:1017–1023
  87. Itani KM, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents. 2005;26:442–448
  88. Sharpe JN, Shively EH, Polk HC. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2005;189:425–428
  89. Mascini EM, Jansze M, Schouls LM, Verhoef J, Van Dijk H. Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. Int J Antimicrob Agents. 2001;18:395–398
  90. Stevens DL, Maier KA, Mitten JE. Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother. 1987;31:213–218
  91. Stevens DL, Laine BM, Mitten JE. Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens. Antimicrob Agents Chemother. 1987;31:312–316
  92. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988;158:23–28
  93. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med. 1996;334:240–245
  94. Vazquez-Aragon P, Lizan-Garcia M, Cascales-Sanchez P, Villar-Canovas MT, Garcia-Olmo D. Nosocomial infection and related risk factors in a general surgery service: a prospective study. J Infect. 2003;46:17–22
  95. Jarvis WR. Infection control and changing health-care delivery systems. Emerg Infect Dis. 2001;7:170–173
  96. Ogawa K, Hirai M, Katsube T, et al. Suppression of cellular immunity by surgical stress. Surgery. 2000;127:329–336
  97. McEachern R, Campbell GD. Hospital-acquired pneumonia: epidemiology, etiology, and treatment. Infect Dis Clin North Am. 1998;12:761–779
  98. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States (National Nosocomial Infections Surveillance System). Crit Care Med. 1999;27:887–892
  99. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416
  100. American Thoracic Society, November 1995. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies (A consensus statement). Am J Respir Crit Care Med. 1996;153:1711–1725
  101. Grossman RF, Fein A. Evidence-based assessment of diagnostic tests for ventilator-associated pneumonia (Executive summary). Chest. 2000;117(4 suppl 2):177S–181S
  102. Shorr AF, Sherner JH, Jackson WL, Kollef MH. Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis. Crit Care Med. 2005;33:46–53
  103. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290:2588–2598
  104. D’Amico R, Pifferi S, Leonetti C, Torri V, Tinazzi A, Liberati A. Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials. BMJ. 1998;316:1275–1285
  105. Nathens AB, Marshall JC. Selective decontamination of the digestive tract in surgical patients: a systematic review of the evidence. Arch Surg. 1999;134:170–176
  106. Gastinne H, Wolff M, Delatour F, Faurisson F, Chevret S. A controlled trial in intensive care units of selective decontamination of the digestive tract with nonabsorbable antibiotics (The French Study Group on Selective Decontamination of the Digestive Tract). N Engl J Med. 1992;326:594–599
  107. Sanchez Garcia M, Cambronero Galache JA, Lopez Diaz J, et al. Effectiveness and cost of selective decontamination of the digestive tract in critically ill intubated patients (A randomized, double-blind, placebo-controlled, multicenter trial). Am J Respir Crit Care Med. 1998;158:908–916
  108. Verwaest C, Verhaegen J, Ferdinande P, et al. Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit. Crit Care Med. 1997;25:63–71
  109. de La Cal MA, Cerda E, Garcia-Hierro P, et al. Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo-controlled, double-blind trial. Ann Surg. 2005;241:424–430
  110. Kollef MH. Selective digestive decontamination should not be routinely employed. Chest. 2003;123(suppl 5):464S–468S
  111. Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med. 1998;129:433–440
  112. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998;157:531–539
  113. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J Respir Crit Care Med. 2005;171:388–416
  114. Bjork DT, Pelletier LL, Tight RR. Urinary tract infections with antibiotic resistant organisms in catheterized nursing home patients. Infect Control. 1984;5:173–176
  115. Krieger JN, Kaiser DL, Wenzel RP. Nosocomial urinary tract infections cause wound infections postoperatively in surgical patients. Surg Gynecol Obstet. 1983;156:313–318
  116. Leone M, Albanese J, Garnier F, et al. Risk factors of nosocomial catheter-associated urinary tract infection in a polyvalent intensive care unit. Intensive Care Med. 2003;29:1077–1080
  117. Hedrick TL, Sawyer RG. Health-care-associated infections and prevention. Surg Clin North Am. 2005;85:1137–1152
  118. Tambyah PA, Knasinski V, Maki DG. The direct costs of nosocomial catheter-associated urinary tract infection in the era of managed care. Infect Control Hosp Epidemiol. 2002;23:27–31
  119. Stark RP, Maki DG. Bacteriuria in the catheterized patient (What quantitative level of bacteriuria is relevant?). N Engl J Med. 1984;311:560–564
  120. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128–140
  121. Maki DG, Tambyah PA. Engineering out the risk for infection with urinary catheters. Emerg Infect Dis. 2001;7:342–347
  122. Harding GK, Nicolle LE, Ronald AR, et al. How long should catheter-acquired urinary tract infection in women be treated? (A randomized controlled study). Ann Intern Med. 1991;114:713–719
  123. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40:643–654
  124. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women (Infectious Diseases Society of America (IDSA)). Clin Infect Dis. 1999;29:745–758
  125. Jain P, Parada JP, David A, Smith LG. Overuse of the indwelling urinary tract catheter in hospitalized medical patients. Arch Intern Med. 1995;155:1425–1429
  126. Guidelines for preventing catheter associated urinary tract infections–on Internet for consultation. Commun Dis Rep CDR Wkly. 2000;10(17):149
  127. van der Wall E, Verkooyen RP, Mintjes-de Groot J, et al. Prophylactic ciprofloxacin for catheter-associated urinary-tract infection. Lancet. 1992;339:946–951
  128. Vollaard EJ, Clasener HA, Zambon JV, Joosten HJ, van Griethuysen AJ. Prevention of catheter-associated gram-negative bacilluria with norfloxacin by selective decontamination of the bowel and high urinary concentration. J Antimicrob Chemother. 1989;23:915–922
  129. Verbrugh HA, Mintjes-de Groot AJ, Andriesse R, Hamersma K, van Dijk A. Postoperative prophylaxis with norfloxacin in patients requiring bladder catheters. Eur J Clin Microbiol Infect Dis. 1988;7:490–494
  130. Britt MR, Garibaldi RA, Miller WA, Hebertson RM, Burke JP. Antimicrobial prophylaxis for catheter-associated bacteriuria. Antimicrob Agents Chemother. 1977;11:240–243
  131. Platt R, Polk BF, Murdock B, Rosner B. Prevention of catheter-associated urinary tract infection: a cost-benefit analysis. Infect Control Hosp Epidemiol. 1989;10:60–64
  132. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001;32:1249–1272
  133. National Nosocomial Infections Surveillance (NNIS). System Report (Data summary from January 1992 through June 2004, issued October 2004). Am J Infect Control. 2004;32:470–485
  134. Oncu S, Ozsut H, Yildirim A, et al. Central venous catheter related infections: risk factors and the effect of glycopeptide antibiotics. Ann Clin Microb Antimicrob. 2003;2:3
  135. Pelletier SJ, Crabtree TD, Gleason TG, Pruett TL, Sawyer RG. Bacteremia associated with central venous catheter infection is not an independent predictor of outcomes. J Am Coll Surg. 2000;190:671–680
  136. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA. 1999;282:554–560
  137. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter (A randomized, controlled trial). Ann Intern Med. 1997;127:257–266
  138. Hanna HA, Raad II, Hackett B, et al. Antibiotic-impregnated catheters associated with significant decrease in nosocomial and multidrug-resistant bacteremias in critically ill patients. Chest. 2003;124:1030–1038
  139. O’Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections (Centers for Disease Control and Prevention). MMWR Recomm Rep. 2002;51(RR-10):1–29
  140. Eggimann P, Harbarth S, Constantin MN, Touveneau S, Chevrolet JC, Pittet D. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. Lancet. 2000;355:1864–1868
  141. Raad II, Hohn DC, Gilbreath BJ, et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol. 1994;15(4 pt 1):231–238
  142. Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet. 1991;338:339–343
  143. Sheth NK, Franson TR, Rose HD, Buckmire FL, Cooper JA, Sohnle PG. Colonization of bacteria on polyvinyl chloride and Teflon intravascular catheters in hospitalized patients. J Clin Microbiol. 1983;18:1061–1063
  144. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can Med Assoc J. 2004;171:466–472
  145. Privitera G, Scarpellini P, Ortisi G, Nicastro G, Nicolin R, de Lalla F. Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother. 1991;35(1):208–210
  146. Bouza E, Munoz P, Alonso R. Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin Microbiol Infect. 2005;11(suppl 4):57–64
  147. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis (American College of Gastroenterology, Practice Parameters Committee). Am J Gastroenterol. 1997;92:739–750
  148. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med. 1989;86:15–19
  149. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591–1597
  150. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005;40:1586–1590
  151. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996;22:813–818
  152. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet. 1983;2:1043–1046
  153. Bricker E, Garg R, Nelson R, Loza A, Novak T, Hansen J. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. 2005;1:CD004610
  154. Young GP, Ward PB, Bayley N, et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology. 1985;89:1038–1045
  155. Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea (A randomized double-blind trial). Arch Intern Med. 1986;146:1101–1104
  156. Malnick SD, Zimhony O. Treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother. 2002;36:1767–1775
  157. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis. 2002;35:690–696
  158. Friedenberg F, Fernandez A, Kaul V, Niami P, Levine GM. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum. 2001;44:1176–1180
  159. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769–1775
  160. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol. 1985;80:867–868
  161. Buggy BP, Fekety R, Silva J. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol. 1987;9:155–159
  162. Cavagnaro C, Berezin S, Medow MS. Corticosteroid treatment of severe, non-responsive Clostridium difficile induced colitis. Arch Dis Child. 2003;88:342–344
  163. Beales IL. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut. 2002;51:456
  164. Leung DY, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr. 1991;118(4 pt 1):633–637
  165. Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol. 2000;95(suppl 1):S11–S13
  166. Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis. 2003;35(6-7):365–367
  167. Plummer S, Weaver MA, Harris JC, Dee P, Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol. 2004;7:59–62
  168. Marty FM, Rubin RH. The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy. Transpl Int. 2006;19:2–11
  169. Tolkoff-Rubin NE, Cosimi AB, Russell PS, Rubin RH. A controlled study of trimethoprim-sulfamethoxazole prophylaxis of urinary tract infection in renal transplant recipients. Rev Infect Dis. 1982;4:614–618
  170. Tolkoff-Rubin NE, Rubin RH. Urinary tract infection in the immunocompromised host (Lessons from kidney transplantation and the AIDS epidemic). Infect Dis Clin North Am. 1997;11:707–717
  171. Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med. 1990;89:255–274
  172. Torre-Cisneros J, De la Mata M, Pozo JC, et al. Randomized trial of weekly sulfadoxine/pyrimethamine vs.daily low-dose trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clin Infect Dis. 1999;29:771–774
  173. Tolkoff-Rubin NE, Rubin RH. Opportunistic fungal and bacterial infection in the renal transplant recipient. J Am Soc Nephrol. 1992;2(suppl 12):S264–S269
  174. Baden LR, Katz JT, Franck L, et al. Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole. Transplantation. 2003;75:339–343
  175. Pescovitz MD. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation. 2006;82(suppl 2):S4–S8
  176. Pelletier SJ, Crabtree TD, Gleason TG, et al. Characteristics of infectious complications associated with mortality after solid organ transplantation. Clin Transplant. 2000;14(4 pt 2):401–408
  177. 65+ in the United States: 2005. 2005. http://www.census.gov/prod/2006pubs/p23-209.pdf.
  178. Dominioni L, Imperatori A, Rotolo N, Rovera F. Risk factors for surgical infections. Surg Infect (Larchmt). 2006;7(suppl 2):S9–S12

PII: S0011-3840(07)00107-4

doi: 10.1067/j.cpsurg.2007.06.006

Current Problems in Surgery
Volume 44, Issue 10 , Pages 635-675 , October 2007

Article Tools

* Image Usage & Resolution